title: Prostate cancer: the role of hormonal therapy.
abstract: Prostate cancer is the cause of more than 1% of all deaths in men. Its incidence is increasing by 2-3% per year. The general prognosis for diagnosed prostate cancer remains poor, with 70% survival at 10 years compared to the general population. About 50% of the cases are diagnosed at a locally advanced stage, and about 30% have bone metastases at the time of diagnosis. Adjuvant systemic treatments (hormones or chemotherapy), which are effective for advanced-stage disease, might have a greater role in early-stage disease. Advanced prostate cancer is an incurable disease. Treatment objective is palliation only. Here, we review the major controversies concerning hormonal therapy, and provide a general approach to management of patients with early-stage and advanced prostate cancer.
authors.affiliation: Dept. of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Salesi
authors.forename: P
authors.initials: P
authors.lastname: Carlini
authors.forename: E M
authors.initials: EM
authors.lastname: Ruggeri
authors.forename: G
authors.initials: G
authors.lastname: Ferretti
authors.forename: E
authors.initials: E
authors.lastname: Bria
authors.forename: F
authors.initials: F
authors.lastname: Cognetti
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone